At BioStock Investor Meeting in Stockholm, Cereno Scientific’s CEO Sten R. Sörensen talked about how the company’s ongoing phase II study with lead candidate CS1 is progressing as well as about the company’s preclinical programs. Moreover, the exercise period for warrants of series TO2 in Cereno Scientific runs between 14 and 28 September. Cereno Scientific’s Chief Medical Officer Björn Dahlöf also participated in the Q&A session.
See Cereno Scientific’s presentation below.The content of BioStock’s news and analyses is independent but the work of BioStock is to a certain degree financed by life science companies. The above article concerns a company from which BioStock has received financing.